High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention
Authors:
Open Access
Abstract
Background A low level of high-density lipoprotein cholesterol (HDL-C) is strongly associated with cardiovascular events. However, the significance of HDL-C after statin therapy on the outcome of patients who have undergone percutaneous coronary intervention (PCI) with drug eluting stents (DES) is unclear. Objectives To investigate the significance of HDL-C after statin therapy on cardiovascular events in patients with coronary artery disease after DES implantation. Methods Patients who underwent PCI with DES from January 2004 to December 2009 were prospectively enrolled. The follow-up lipid panel of 2693 patients (median lab follow-up duration 225 days) who had continued using statins after PCI and who attained low-density lipoprotein cholesterol (LDL-C) Results Median follow-up duration was 832 days. 1585 (58.9%) patients had low follow-up HDL-C and 1108 had high follow-up HDL-C. The low follow-up HDL-C group had significantly higher rates of MACE. Low follow-up HDL-C was a significant independent predictor of MACE (adjusted HR 1.404, 95% CI 1.111 to 1.774, p=0.004). In further analysis with propensity scores matching, overall findings were consistent. Conclusions Raising HDL-C levels may be a subsequent goal after achieving target LDL-C levels in patients with DES implantation.Keywords
This publication has 39 references indexed in Scilit:
- Individualising the risks of statins in men and women in England and Wales: population-based cohort studyHeart, 2010
- Statins in prevention of repeat revascularization after percutaneous coronary intervention—A meta-analysis of randomized clinical trialsPharmacological Research, 2010
- Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)The American Journal of Cardiology, 2009
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media ThicknessNew England Journal of Medicine, 2009
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Prevalence of Low High-Density Lipoprotein Cholesterol in Patients With Documented Coronary Heart Disease or Risk Equivalent and Controlled Low-Density Lipoprotein CholesterolThe American Journal of Cardiology, 2007
- Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary AtherosclerosisJAMA, 2007
- High-Density Lipoprotein and Cardiovascular RiskCirculation, 2004
- Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese populationThe American Journal of Cardiology, 2001
- Atherosclerosis and the Arterial Smooth Muscle CellScience, 1973